| Literature DB >> 25879586 |
Muhammad Usman Amin1, Muhammad Khurram2, Baharullah Khattak3, Jafar Khan4.
Abstract
BACKGROUND: To determine the effect of flavonoids in conjunction with antibiotics in methicillin resistant Staphylococcus aureus (MRSA) a study was designed. The flavonoids included Rutin, Morin, Qurecetin while antibiotics included ampicillin, amoxicillin, cefixime, ceftriaxone, vancomycin, methicillin, cephradine, erythromycin, imipenem, sulphamethoxazole/trimethoprim, ciprofloxacin and levolfloxacin. Test antibiotics were mostly found resistant with only Imipenem and Erythromycin found to be sensitive against 100 MRSA clinical isolates and S. aureus (ATCC 43300). The flavonoids were tested alone and also in different combinations with selected antibiotics.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25879586 PMCID: PMC4364681 DOI: 10.1186/s12906-015-0580-0
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Flavonoids used in antibiotic sensitivity assays
|
|
|
|---|---|
| Morin (M) | 100 μg, 200 μg, 300 μg, 400 μg, 500 μg |
| Rutin (R) | 100 μg, 200 μg, 300 μg, 400 μg, 500 μg |
| Quercetin (Q) | 100 μg, 200 μg, 300 μg |
Test concentrations of flavonoids and their combination for MIC assays
|
|
| |||
|---|---|---|---|---|
|
|
| |||
|
|
|
|
| |
| Morin (M) | NT* | NT | NT | NT |
| Rutin(R) | NT | NT | NT | NT |
| Quercetin(Q) | 600 | 75 | 300 | 180 |
| Morin + Rutin(M + R) | 800 + 800 | 100 + 100 | 500 + 500 | 380 + 380 |
| Morin + Rutin + Quercetin (M + R + Q) | 600 + 600 + 400 | 150 + 150 + 100 | 400 + 400 + 260 | 260 + 260 + 120 |
† To determine Exact MIC’s of test substances an incremental increase approach was adopted with 20 μg decrease in each dilution.
*Not tested.
Average Zone of Inhibitions (in millimeters ± STDEV) of Morin, Rutin, Quercetin, Morin + Rutin, Quercetin + Rutin, Quercetin + Morin, and Morin + Quercetin + Rutin against MRSA clinical isolates and (ATCC 43300)
|
|
|
|
|---|---|---|
| M | 0 | 0 |
| R | 0 | 0 |
| Q | 13.5 ± 0.21 | 13.33 ± 0.26 |
| M + R | 11.5 ± 0.22 | 11.58 ± 0.21 |
| Q + R | 0 | 0 |
| Q + M | 0 | 0 |
| M + Q + R | 16.5 ± 0.21 | 16.23 ± 0.26 |
Average zone of inhibitions (in mm ± STDEV) of antibiotics alone and with flavonoid/(s) against (ATCC 43300) and MRSA clinical isolates (n =100)
|
|
|
|
| |
|---|---|---|---|---|
|
| 0 | 14.5 ± 0.29 | 13.5 ± 0.21 | 23.50 ± 1.1 |
| AMO * | 0 | 14.18 ± 0.36 | 13.33 ± 0.26 | 23.73 ± 1.1 |
|
| 0 | 11.5 ± 0.22 | 17 ± 0.29 | 22.5 ± 1.2 |
| AMP * | 0 | 11.58 ± 0.21 | 17.33 ± 0.30 | 22.63 ± 1.2 |
|
| 0 | 14.5 ± 0.32 | 18.5 ± 0.31 | 24.55 ± 1.00 |
| CEPH* | 0 | 14.18 ± 0.29 | 18.33 ± 0.30 | 24.22 ± 1.00 |
|
| 0 | 16.5 ± 0.30 | 20.5 ± 1.00 | 27 ± 1.20 |
| CET* | 0 | 16.18 ± 0..29 | 20.83 ± 1.00 | 27.24 ± 1.23 |
|
| 16 ± 0.90 | 19.5 ± 0.58 | 22 ± 1.10 | 28 ± 1.00 |
| IMP* | 16.18 ± 0.92 | 19.62 ± 0.31 | 22.18 ± 1.12 | 28.21 ± 0.90 |
|
| 0 | 13.5 ± 0.31 | 16.5 ± 0.28 | 21.5 ± 1.1 |
| ME* | 0 | 13.18 ± 39 | 16.89 ± 0.29 | 21.73 ± 1.0 |
|
| 18 ± 0.59 | 18 ± 0.59 | 18 ± 0.59 | 18 ± 0.59 |
| VAN* | 17.37 ± 0.80 | 17.37 ± 0.80 | 17.37 ± 0.80 | 17.37 ± 0.80 |
|
| 14 ± 0.91 | 9 ± 0.25 | 6.5 ± 0.21 | 3 ± 0.24 |
| LEV* | 13.88 ± 1.21 | 9.52 ± 0.25 | 6.85 ± 0.22 | 3.23 ± 0..25 |
|
| 10.5 ± 2.5 | 7.24 ± 0.19 | 4 ± 0.22 | 2.25 ± 0.24 |
| CIP* | 13.1 ± 3.1 | 8.1 ± 0.18 | 4.35 ± 0.24 | 2.73 ± 0.21 |
|
| 22 ± 1.36 | 22 ± 1.36 | 22 ± 1.36 | 22 ± 1.36 |
| ERY* | 20.96 ± 2.1 | 20.96 ± 1.10 | 20.96 ± 1.10 | 20.96 ± 1.1 |
|
| 0 | 11.5 ± 0.22 | 13 ± 0.21 | 14 ± 0.21 |
| S-T* | 0 | 11.58 ± 0.21 | 13.33 ± 0.26 | 14.23 ± 0.26 |
|
| 0 | 11.5 ± 0.22 | 13 ± 0.21 | 14 ± 0.21 |
| CEF* | 0 | 11.58 ± 0.21 | 13.33 ± 0.26 | 14.23 ± 0.26 |
† activity against S. aureus (ATCC 43300).
*activity against clinical isolates.
MICs of flavonoid/(s) against (ATCC 43300) and clinical isolates of MRSA
|
|
|
|
|---|---|---|
| M + R | 400 + 400 | 400 + 400 (n = 14) |
| 800 + 800 (n = 86) | ||
| Q | 300 | 300 (n = 64) |
| 600 ( n = 36) | ||
| M + R+ Q | 200 + 300 + 300 | 200 + 300 + 300 (n = 60) |
| 200 + 600 + 600 (n = 40) |
† activity against S. aureus (ATCC 43300).
*activity against clinical isolates.
Exact MICs (μg/ml) of flavonoid/(s) against (ATCC 43300) and clinical isolates of MRSA
|
|
|
| |
|---|---|---|---|
|
| 400 | 260 | (280)♣ + 140 |
| Clinical Isolates | 427.40a ± 14.40 | 279.00a ± 14.65 | (303.56) |
| MIC Ranges | 400 - 440 | 260 – 300 | M + R = 280 – 340 |
| Q = 140 – 200 |
♣= MIC’s of M & R are same in combination.
a= Average value.
Exact MICs (μg/ml) of flavonoid/(s) with antibiotics against (ATCC 43300) and clinical isolates of MRSA
|
|
|
| |
|---|---|---|---|
|
|
|
|
|
| AMO* | 367.40 ± 15.71 | 279.00a ± 14.65 | (163.56a) |
| MIC range* | 340 - 380 | 260 - 320 | M + R = 140 – 200; Q = 80 – 140 |
|
|
|
|
|
| AMP* | 427.40a ± 14.40 | 178.80a ± 14.25 | (186.56a) |
| MIC range* | 400 - 440 | 160 - 200 | M + R = 160–220; Q = 80 – 140 |
|
|
|
|
|
| CEPH* | 367.40 ± 15.71 | 178.80a ± 14.25 | (163.56a) |
| MIC range* | 340 - 380 | 160 - 200 | M + R = 140 – 200; Q = 60 – 120 |
|
|
|
|
|
| CET* | 347.40 ± 12.92 | 158.60a ± 15.11 | (162.94a) |
| MIC range* | 320 - 360 | 140 - 180 | M + R = 140 – 180; Q = 40 -100 |
|
|
|
|
|
| IMP* | 327.80a ± 14.85 | 138.80a ± 14.99 | (148.31a) |
| MIC range* | 300 - 340 | 120 - 160 | M + R = 120–180 ; Q = 40 – 100 |
|
|
|
|
|
| ME* | 387.40 ± 15.78 | 196.70a ± 12.75 | (208.51a) |
| MIC range* | 360 - 400 | 180 - 220 | M + R = 180 – 240; Q = 80-160 |
♣MIC of M & R is same.
a= Average value.
*against MRSA clinical isolates (n = 100).
† against S. aureus (ATCC 43300).
Exact MICs (μg/ml) of antibiotics with flavonoid/(s) against (ATCC 43300) and clinical isolates of MRSA
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
|
|
|
| AMO * | 197.70a ± 64.02 | 49.43a ± 16.03 | 197.70a ± 64.02 | 6.00a ± 2.13 |
| MIC range* | 128 – 256 | 32 - 64 | 128 - 256 | 2-8 |
|
|
|
|
|
|
| AMP * | 162.85a ± 68.05 | 162.85a ± 68.05 | 20.36a ± 8.51 | 5.09a ± 2.13 |
| MIC range* | 64 – 256 | 64 - 256 | 8-32 | 2-8 |
|
|
|
|
|
|
| CEPH* | 200.96 a ± 63.69 | 50.38 a ± 17.92 | 25.12a ± 7.92 | 6.28a ± 1.99 |
| MIC range* | 128 – 256 | 32 - 64 | 16 - 32 | 4-8 |
|
|
|
|
|
|
| CET* | 67.52 a ± 30.48 | 27.09 a ± 16.94 | 8.44a ± 3.81 | 2.11a ± 0.95 |
| MIC range* | 32 – 128 | 16 - 64 | 4 - 16 | 1-4 |
|
|
|
|
|
|
| IMP* | 130.88 a ± 84.02 | 32.72 a ± 16.15 | 19.88a ± 10.51 | 4.97a ± 2.63 |
| MIC range* | 32 – 256 | 8 - 64 | 4 - 32 | 1-8 |
|
|
|
|
|
|
| ME* | 135.68 a ± 54.03 | 33.92 a ± 13.51 | 16.96a ± 6.75 | 4.24a ± 1.69 |
| MIC range* | 64 – 256 | 16 - 64 | 8 - 32 | 2-8 |
♣MIC of M & R is same.
a= Average value.
*against MRSA clinical isolates (n = 100).
† against S. aureus (ATCC 43300).
Fractional Inhibitory Concentration indices (FICI) of flavonoid/(s) and antibiotics against (ATCC 43300) and clinical isolates of MRSA
|
|
| ||
|---|---|---|---|
|
|
|
| |
| M + R + AMO | 0.9 | 0.9 | Additive |
| M + R + CEPH | 0.9 | 0.95 | Additive |
| M + R + CET | 0.8 | 0.94 | Additive |
| M + R + IMP | 0.84 | 0.85 | Additive |
| M + R + ME | 0.95 | 0.97 | Additive |
| Q + AMP | 0.74 | 0.77 | Additive |
| Q + CEPH | 0.74 | 0.77 | Additive |
| Q + CET | 0.66 | 0.69 | Additive |
| Q + IMP | 0.66 | 0.69 | Additive |
| Q + ME | 0.82 | 0.83 | Additive |
| M + R + Q + AMO | 0.59 | 0.66 | Additive |
| M + R + Q + AMP | 0.59 | 0.68 | Additive |
| M + R + Q + CEPH | 0.46 | 0.50 | Synergism |
| M + R + Q + CET | 0.31 | 0.44 | Synergism |
| M + R + Q + IMP | 0.32 | 0.45 | Synergism |
| M + R + Q + ME | 0.45 | 0.5 | Synergism |
Potassium leakage (ppm) by flavonoid/(s) against (ATCC 43300) and clinical isolates of MRSA
|
|
|
|
| |
|---|---|---|---|---|
|
| 10.2 | 28.4 | 26.4 | 32.7 |
| Clinical Isolates | 10.19 ± 0.18 | 28.49 ± 0.14 | 26.49 ± 0.12 | 32.29 ± 0.13 |
♣MIC of M & R is same.
Potassium leakage (ppm) by flavonoid/(s) with antibiotics against (ATCC 43300) and clinical isolates of MRSA
|
|
|
|
|
|
|---|---|---|---|---|
|
| 25.7 | 32.3 | NT | 41 |
| AMO * | 25.79 ± 0.16 | 32.40 ± 0.13 | NT | 41.09 ± 0.11 |
|
| 25.6 | NT | 34.4 | 39.6 |
| AMP * | 25.69 ± 0.13 | NT | 34.49 ± 0.14 | 39.83 ± 0.12 |
|
| 25.70 | 33.20 | 35.2 | 40 |
| CEPH* | 25.89 ± 0.14 | 33.30 ± 0.14 | 35.39 ± 0.14 | 40.10 ± 0.10 |
|
| 25.9 | 34.60 | 37.5 | 42.6 |
| CET* | 25.96 ± 0.10 | 34.69 ± 0.15 | 37.59 ± 0.10 | 42.69 ± 0.13 |
|
| 26.6 | 36.6 | 39.2 | 44.7 |
| IMP* | 26.79 ± 0.14 | 36.79 ± 0.15 | 39.26 ± 0.14 | 45.89 ± 0.14 |
|
| 25.1 | 31.4 | 34.3 | 39.2 |
| ME* | 25.29 ± 0.12 | 31.52 ± 0.13 | 34.43 ± 0.11 | 39.33 ± 0.12 |
*against MRSA clinical isolates (n = 100).
† against S. aureus (ATCC 43300).
NT = Not tested.